GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Cash And Cash Equivalents

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Cash And Cash Equivalents : $0.04 Mil (As of Apr. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Cash And Cash Equivalents?

Advanced Proteome Therapeutics's quarterly cash and cash equivalents declined from Oct. 2022 ($0.31 Mil) to Jan. 2023 ($0.24 Mil) but then stayed the same from Jan. 2023 ($0.24 Mil) to Apr. 2023 ($0.04 Mil).

Advanced Proteome Therapeutics's annual cash and cash equivalents increased from Jul. 2020 ($0.00 Mil) to Jul. 2021 ($0.82 Mil) but then declined from Jul. 2021 ($0.82 Mil) to Jul. 2022 ($0.54 Mil).


Advanced Proteome Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Advanced Proteome Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Cash And Cash Equivalents Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.13 - 0.82 0.54

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.54 0.31 0.24 0.04

Advanced Proteome Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Advanced Proteome Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines